Dr. Yednock joined Annexon in 2013, serving as Chief Scientific Officer (CSO) until October 2021 when he became Chief Innovation Officer. Dr. Yednock was previously CSO for Prothena Corporation, Head of Research for Elan Pharmaceuticals and a Scientist at Athena Neurosciences. While at Athena, he was the scientific inventor of Tysabri®, a blockbuster monoclonal antibody for the treatment of multiple sclerosis. In addition to his work in multiple sclerosis, Dr. Yednock has contributed to the invention or progression of numerous drugs in the areas of Alzheimer’s disease, Parkinson’s disease, amyloidosis, rheumatoid arthritis, psoriasis and Crohn’s disease. Dr. Yednock earned his BS in biology and chemistry from the University of Illinois and his PhD in anatomy and cell biology from the University of California San Francisco.